ArticleJACC. Case reports2026
Testosterone-Induced Heart Failure in a Professional Dancer.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecreational anabolic-androgenic steroid (AAS) use is common among noncompetitive adults and is strongly associated with increased cardiovascular risk. CASE SUMMARY: A 34-year-old professional dancer presented with 1 month of progressive dyspnea on exertion and orthopnea in the setting of testosterone use. Transthoracic echocardiogram revealed a left ventricular (LV) ejection fraction of 16%, global LV hypokinesis, and LV dilation. He was diagnosed with nonischemic cardiomyopathy, initiated on diuresis and guideline-directed medical therapy, and counseled on avoidance of testosterone. DISCUSSION: AAS users have a significantly higher incidence of acute myocardial infarction, coronary intervention, venous thromboembolism, arrhythmia, and heart failure compared with matched control patients. Although some markers of cardiac function recover after cessation, others remain impaired. TAKE-HOME MESSAGES: AAS use is common among adult recreational athletes and is an underrecognized cause of LV dysfunction and heart failure. Early recognition, diagnosis, and cessation of AAS can significantly improve cardiac function and at least partially reverse AAS-associated cardiotoxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.